CEVR analyzes the benefits, risks, and costs of strategies to improve health and health care.

About Us
Data

News & Events

Recent Publications

Is an orphan drug's cost-effectiveness associated with US health plan coverage restrictiveness?

PharmaoEconomics

Chambers JD, Margaretos NM, Enright DE, Wang R, Ye X. Is an Orphan Drug's Cost-Effectiveness Associated with US Health Plan Coverage Restrictiveness? Pharmacoeconomics. 2021 Oct 26. doi: 10.1007/s40273-021-01096-5

Frequency and impact of the inclusion of broader measures of value in economic evaluations of vaccines

Vaccine

Madison C. Silver, Peter J. Neumann, Siyu Ma, David D. Kim, Joshua T. Cohen, Mawuli Nyaku, Craig Roberts, Anushua Sinha, Daniel A. Ollendorf, Frequency and impact of the inclusion of broader measures of value in economic evaluations of vaccines, Vaccine, 2021,

Variation in access to hemophilia A treatments in the United States

Journal of Medical Economics

Margaretos NM, Patel AM, Panzer AD, Lai RC, Whiteley J, Chambers JD. Variation in access to hemophilia A treatments in the United States. J Med Econ. 2021 Jan-Dec;24(1):1143-1148

Valuing Alzheimer disease therapies—Considering costs and benefits beyond the patient

JAMA Network Open

Lin P, Neumann PJ. Valuing Alzheimer Disease Therapies—Considering Costs and Benefits Beyond the Patient. JAMA Netw Open. 2021;4(10):e2131913. doi:10.1001/jamanetworkopen.2021.31913

Variation in health plan coverage of ESAs for anemia due to chronic kidney disease

Journal of Managed Care + Specialty Pharmacy

Margaretos NM, Panzer AD, Lai RC, Sanon M, Michalopoulos E, Redmond A, Moghadam R, Chambers JD. Variation in health plan coverage of ESAs for anemia due to chronic kidney disease, J Manag Care Spec Pharm, 2021 Sep;27(9):1221-1229

Clinically-driven payment and benefit design to improve health equity: The case of obesity prevention and treatment

Health Affairs Blog

Kim DD, Griauzde DH, Richardson CR, Fendrick AM. Clinically-driven payment and benefit design to improve health equity: The case of obesity prevention and treatment. Health Affairs Blog. September 10, 2021.

Limited role of patient input in specialty drug coverage policies

Journal of Managed Care & Specialty Pharmacy

D’Cruz B, Graff JS, Panzer AD, Chambers JD. Limited role of patient input in specialty drug coverage policies. Journal of Managed Care & Specialty Pharmacy 2021;27(8):1067–76.

How does cost-effectiveness analysis inform health care decisions?

AMA Journal of Ethics

Kim DD, Basu A. How does cost-effectiveness analysis inform health care decisions? AMA J Ethics. 2021;23(8):E639-647.

Dementia diagnosis disparities by race and ethnicity

Medical Care

Lin PJ, Daly AT, Olchanski N, Cohen JT, Neumann PJ, Faul JD, Fillit HM, Freund KM. Dementia diagnosis disparities by race and ethnicity. Medical Care 2021;59(8):679–86.

Medicare ‘coverage with evidence development’ for Aducanumab? How might it work?

Health Affairs Blog

Chambers J, Lin P, Tunis SR, Neumann PJ, Medicare ‘Coverage With Evidence Development’ For Aducanumab? How Might It Work? Health Affairs, June 30, 2021.

Bridging the gap: aligning economic research with disease burden

BMJ Global Health

Do LA, Synnott PG, Ma S, Ollendorf DA. Bridging the gap: aligning economic research with disease burden. BMJ Global Health 2021;6(6).

Value‐based drug pricing in the Biden era: Opportunities and prospects

Health Services Research

Neumann PJ, Ollendorf DA, Cohen JT. Value‐based drug pricing in the Biden era: Opportunities and prospects. Health Services Research 2021.

External reference pricing: The drug-pricing reform America needs?

The Commonwealth Fund Issues Brief

Ollendorf DA, Synnott PG, Neumann PJ. "External reference pricing: The drug-pricing reform America needs?," The Commonwealth Fund Issues Brief, May 27, 2021.

A next frontier in health care transparency: payer drug coverage policy

Health Affairs Blog

Chambers JD, Neumann PJ. "A next frontier in health care transparency: payer drug coverage policy," Health Affairs Blog, April 7, 2021.

An evidence review of low-value care recommendations: Inconsistency and lack of economic evidence considered

Journal Of General Internal Medicine

Kim DD, Do LA, Daly AT, Wong JB, Chambers JD, Ollendorf DA, Neumann PJ. An Evidence Review of Low-Value Care Recommendations: Inconsistency and Lack of Economic Evidence Considered. J Gen Intern Med. 2021 Feb 23.

The CEVR Team

Our team of experienced, dedicated researchers is led by health economists Peter Neumann and Josh Cohen. Together we produce cutting-edge health care cost-effectiveness research.

Meet the CEVR Team

Our Databases

Our comprehensive databases provide the information individuals and organizations need to analyze the benefits, risks, and costs of strategies to improve health and health care.